^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MSLN CAR-T

    i
    Associations
    News

    Trials

    Company:
    National Cancer Institute
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto) (NCT04981691)
    Phase 1
    Ruijin Hospital
    Recruiting
    Last update posted :
    09/17/2021
    Initiation :
    10/01/2021
    Primary completion :
    01/09/2022
    Completion :
    07/09/2022
    MSLN
    |
    MSLN positive
    |
    cyclophosphamide • MSLN CAR-T • UCLM802
    Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. (NCT03545815)
    Phase 1
    Chinese PLA General Hospital
    Unknown status
    Last update posted :
    08/10/2020
    Initiation :
    03/19/2018
    Primary completion :
    10/30/2020
    Completion :
    12/30/2020
    MSLN
    |
    MSLN positive
    |
    GC008t • MPTK-CAR-T cells • MSLN CAR-T
    Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer (NCT03692637)
    Phase 1
    Allife Medical Science and Technology Co., Ltd.
    Unknown status
    Last update posted :
    01/31/2019
    Initiation :
    03/01/2019
    Primary completion :
    11/01/2020
    Completion :
    11/01/2021
    PD-L1 • PD-1 • MSLN
    |
    MSLN expression • MSLN positive
    |
    MSLN CAR-T • anti-Mesothelin CAR NK Cells
    Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors (NCT02930993)
    Phase 1
    China Meitan General Hospital
    Unknown status
    Last update posted :
    10/12/2016
    Initiation :
    08/01/2016
    Primary completion :
    08/01/2018
    Completion :
    08/01/2019
    MSLN
    |
    MSLN positive
    |
    cyclophosphamide • MSLN CAR-T • anti-mesothelin CAR T cells